Issue 134

Next month the PSYCH Symposium returns to the iconic British Museum, bringing together 350+ innovators, academics, business leaders & investors to shine a light on the emerging European psychedelic medicine industry.

With an action-packed agenda featuring research updates into specific areas of treatment, debates and networking amongst key stakeholders, the conference will look at the practical next steps for this sector.

Ticket prices rise at midnight. Book your tickets today to save £50+ per ticket.

BOOK YOUR TICKETS

NEGEV CAPITAL CONFIDENT BIG PHARMA WILL EMBRACE PSYCHEDELIC MEDICINE

Ken Belotsky, Partner at Negev Capital, discusses investment opportunities and the importance of PSYCH Symposium.

Read More

FRESH INSIGHTS INTO THE MECHANISM OF ACTION OF PSYCHEDELIC MEDICINES

A new study suggests antidepressant effects and the hallucinatory effects may have separate mechanisms.

Read More

BUSINESS AND INVESTMENT

PharmaTher provides corporate update. The company had roughly C$6 million in cash at the end of May 2023.

Life sciences industry boosted by increased M&A activity. Companies spent US$85 billion in the first half of 2023.

Report analyses ayahuasca consumption worldwide. The survey estimates more than four million people have consumed the psychoactive medicine.

Numinus appoints new Chief Financial Officer. Most recently, Nikhil Handa was CFO at The Supreme Cannabis Company.

Psilera selects non-hallucinogenic drug candidate. In preclinical studies, PSIL-006 was able to treat symptoms of alcohol use disorder.

Would your organisation benefit from engaging with Europe’s psychedelic medicine community?

Would you like to be an official partner of this year’s PSYCH Symposium?

300+ leading investors, policymakers, operators and academics will join us on 6 July in London. We’re expecting a sold-out event at the iconic British Museum, with C-Suite delegates from life sciences, business and finance.

Join our partners Cybin, Clerkenwell Health, Negev Capital and FTI Consulting as Europe looks to become global leader in psychedelic healthcare.

BECOME A SPONSOR

SCIENCE AND RESEARCH

Psychedelic therapy in the treatment of addiction. A review of psychedelic-assisted therapy starting with psychedelic research conducted in the 1950s.

Precision neuroimaging for localisation-related psychiatry. Research into brain mechanisms may reveal biomarkers relevant to psychiatric practice.

REGULATION AND LEGISLATION

Rhode Island House passes bill to legalise psilocybin. Lawmakers voted 54-11 to pass an amended version of the bill.

Canadian healthcare providers fighting to prescribe psychedelic mushrooms. A charter challenge was launched in 2022.

ARTICLES OF INTEREST

UK benefits bill for sick and unable to work to rise by £11 billion. At least 2.55 million people aged 16–64 are not working due to long-term illness.

People who are gay, lesbian or bi have more mental health and substance use problems. They may also experience a general lack of support.

Partner with us